MM&M1h
Post-election prescription: Why Trump’s return could disrupt pharma
From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...
Here’s What An RFK Jr. Health Role In A Trump Administration Could Look Like: Vaccine Skepticism, Fluoride Ban
Kennedy has suggested he would ban fluoride in drinking water after being appointed to an unspecified health post in former ...
Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings
Pre-earnings options volume in Corvus Pharmaceuticals (CRVS) is normal with calls leading puts 8:5. Implied volatility suggests the market is ...
ophthalmologytimes2d
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
Zacks.com on MSN8h
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. These ...
Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show
Shares of Piramal Pharma (PPL) hit a new peak of Rs 307.85, soaring 13 per cent on the BSE in Wednesday’s intra-day trade ...
Pharmabiz1d
Pharmaceutical water systems in transformation mode with advanced processes & shift towards analytics
Pharmaceutical water systems in transformation mode with advanced processes & shift towards analytics: Nandita Vijayasimha, Bengaluru Thursday, November 7, 2024, 08:00 Hrs [IST] I ...
cnbctv183d
Gland Pharma shares jump 11% post Q2 results; Kotak upgrades on limited downside risk
Shares of Gland Pharma Ltd. were trading with gains of up to 10% on Tuesday, November 5. The stock has corrected 24% over ...
Multibagger stock, Sudarshan Pharma declares 1:10 stock split after 400% rally YTD
Stock Market Today: Multibagger stock, Sudarshan Pharma Industries Ltd has declares 1:10 stock split after 400% rally YTD ...
Kauppalehti1d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Topline results are anticipated in Q4 2025 and, assuming positive data, Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. [1] Rosenberger DC, Pogatzki-Zahn EM.
Gland Pharma shares zoom 12% post Q2 results; Kotak upgrades on limited downside
Gland Pharma shares rallied nearly 12% to Rs 1,799 in Monday's trade on BSE after the company reported a 15.7% year-on-year ...